All News
Abst#0788 #ACR21. Forgot to measure vitamin D?
▶️ Red cell distribution width (RDW) inversely correlates w vit D 25(OH) levels prior to MTX
⭐️ RDW ⬆️ after starting MTX, no longer correlates
https://t.co/b5EPDmGE18 @Rheumnow https://t.co/cNN14ErOmF
Links:
Eric Dein ericdeinmd ( View Tweet)
ORAL Surveillance
In mod-severe RA pts >50yo, with CV RF & no hx malignancy, patient-years of exposure required for one event (vs TNFi):
MACE
tofa 5mg bid: 567
tofa 10mg bid: 319
malignancy
tofa 5mg bid: 276
tofa 10mg bid: 275
#ACR21 ABST0831 @RheumNow https://t.co/9vyXPTMFzj
David Liew drdavidliew ( View Tweet)
#ACR21 Abst#0793. Japanese multicenter US cohort (KUDOS) study, looked at difficult to treat (D2T) RA pts
▶️ 1/5 pts are D2T (fail 2+ b/tsDMARD, mod disease or GCs)
⭐️ Contributors of good outcomes: IL-6i (OR 9.6), concomitant MTX (OR 7.1)
@Rheumnow https://t.co/9YSa4ebQlR
Links:
Eric Dein ericdeinmd ( View Tweet)
Greater #comorbidity burden is assoc. w/ worse improvement and disease activity in 1st yr of treatment in ERA @earlyarthritis.
Comorbidities esp affect SJC and patient and physician global assessments.
#ACR21 Abs#0798 @RheumNow
https://t.co/02BRqYp9Yk
Mrinalini Dey DrMiniDey ( View Tweet)
#ACR21 Abst#0801 Early remission at 6 mos is a predictor of long-term remission in patients w new onset RA
▶️ DAS28-CRP, SDAI, CDAI at 6mo predicted remission at 60 months
https://t.co/vWy7EmseZp @Rheumnow https://t.co/HWJSjvFY8d
Links:
Eric Dein ericdeinmd ( View Tweet)
Good news for #COVID vaccine in #SLE. ✅doesn’t cause #lupus flares ➡️ no increase in APS. What about #SARS-CoV2 infection in SLE. Flares ↔️ stable but ⬆️APS Abs. from Hopkins cohort. Petri #ACRBest #ACR21 abst0858 @RheumNow https://t.co/ABx4C4lwvs
Janet Pope Janetbirdope ( View Tweet)
How can we better identify patients with #RA-ILD using #EHRs?
Abs#0561: previously validated algorithms have clinical & research utility when applied to EHRs, esp when well-integrated with key info such as CT chest reports
#ACR21 @RheumNow
https://t.co/OU8BdwqHpc
Mrinalini Dey DrMiniDey ( View Tweet)
ADACTA & MONARCH both showed IL6i monoRx > TNFi monoRx for RA in DBRCTs.
What about in real-world data?
Looking at CorEvitas, less so
LDA: aOR 0.99
MCID in CDAI: 1.06
Even without MTX, both great drug classes for RA
Equally so?
#ACR21 ABST0834 @RheumNow https://t.co/6wvzVrXTW6 https://t.co/fYEktJhZuV
David Liew drdavidliew ( View Tweet)
#ACR21 A#0563 - Is FRAX score applicable for RA? 10 yr Olmsted County epi study: Yes
▶️ 76 osteoporotic fxs in RA pts, FRAX predicted 67 fx (SIR 1.13, not signif)
▶️ 21 observed hip fx, FRAX predicted 23.3 (SIR 0.9)
⭐️ No differences by ages/sex
https://t.co/vWy7EmseZp @Rheumnow https://t.co/8BlzgQYqaV
Links:
Eric Dein ericdeinmd ( View Tweet)
6 year f/up study of sacroilitis in nr-AxSpA pts
⭐️~10% of pts progressed from nr-AxSpa to AS every 2 years
Abs#907
#ACR21
@RheumNow
https://t.co/kiWGmKhpWu
Robert B Chao, MD doctorRBC ( View Tweet)
Watch: What I'm Looking Forward to at #ACR21: Dr. Arthur Kavanaugh
https://t.co/WygW1czwXn https://t.co/1qlZsFBd4Z
Links:
Dr. John Cush RheumNow ( View Tweet)
Guidance on self-efficacy (SE) in IA were published this yr- what factors influence this?
👉PROMs & treatment response determine long-term SE
👉This may help identify pts benefitting most from interventions to improve SE
Abs#0795 #ACR21 @RheumNow
https://t.co/dx28WgxNsE https://t.co/7uN6XctnQb
Mrinalini Dey DrMiniDey ( View Tweet)
#ACR21 Abst#0786. Fibroscan screening for liver injury in pts on MTX:
▶️No significant correlation between cumulative MTX dose and liver stiffness by fibroscan, even at high dose MTX.
⭐️Age, sex, waist circumference, BMI are risks
@Rheumnow https://t.co/IhcNr9fhEh https://t.co/c7TUoGrNZ7
Links:
Eric Dein ericdeinmd ( View Tweet)
In Australia, there's free choice of originator vs biosimilar for etanercept.
Real-world data shows exactly what you'd expect over >48 months - and sometimes it's what you expect that's exactly what you want to see...
OPAL data #ACR21 0840 @RheumNow https://t.co/YJA2Cua9cw
David Liew drdavidliew ( View Tweet)
It was a pleasure to speak to Dr Bryant England about #multimorbidity in #rheumatoidarthritis with a focus on abstract #1924, to be presented at the #Epidemiology & #PublicHealth abstract session on Tuesday #ACR21: https://t.co/qHws6B3fFf
Watch @RheumNow: https://t.co/OKM7WxIEpR
Links:
Mrinalini Dey DrMiniDey ( View Tweet)
The opening quote of the day
#ACR21 @RheumNow https://t.co/gow87jkvfJ
swethaann23 swethaann23 ( View Tweet)
#ACR21 Abst#0449:
Ever wish you had a tool to help you predict which PsA pts will progress to radiographic damage?
➡️Proteomic approaches identified 103 candidate biomarker peptides related to 69 proteins that can potentially do so!
@Rheumnow @uptoTate
https://t.co/uUsZlBLTWC
Links:
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
There are no MRI imaging difference in axSpA with psoriasis, coliitis or iritis. 240 patients in the SASPIC study show psoriatic axSpA similar to axSpA associated with iritis or colitis. Supports the umbrella concept of axSpA @RheumNow #ACR21 Abst#0902 https://t.co/VKTUv22hEJ https://t.co/lOL82ceSn9
Dr. Antoni Chan synovialjoints ( View Tweet)
RheumNow’s expanded coverage of the #ACR21 Annual meeting is sponsored in part by @bmsnews, @JanssenUS, @Novartis. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
#ACR21 Abst#0285
Calculated 10-yr CV risk ↑ w/in 1st yr of new RA dx in 53 Dutch pts:
➤43% had intermediate (I) or high (H) morbidity risk
➤76% had I or H mortality risk
◘ avg 57yo, 74%♀, 72% HTN, & 57% HLD
*️⃣ Early CV risk assessment critical at RA diagnosis!
@Rheumnow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)